CLINICAL TRIALS PROFILE FOR DALTEPARIN SODIUM

All Clinical Trials for dalteparin sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00245856 ↗	Treatment of Upper Extremity Deep-Vein Thrombosis	Completed	Pfizer	Phase 4	2002-09-01	The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.
NCT00245856 ↗	Treatment of Upper Extremity Deep-Vein Thrombosis	Completed	University of Oklahoma	Phase 4	2002-09-01	The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.
NCT00264381 ↗	Management of Superficial Thrombophlebitis	Completed	Pfizer	Phase 4	2002-10-01	The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).
NCT00264381 ↗	Management of Superficial Thrombophlebitis	Completed	University of Oklahoma	Phase 4	2002-10-01	The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).
NCT00655122 ↗	Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study	Terminated	Pfizer	Phase 4	2003-04-01	The primary objective was to study the clinical benefit with dalteparin sodium in thromboprophylaxis in primary care medical subjects. The secondary objective was a pharmacoeconomic evaluation of hromboprophylaxis with dalteparin sodium in primary care medical subjects.
NCT00765063 ↗	The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)	Completed	Pfizer	Phase 2/Phase 3	2008-10-01	The primary objective of this 6 month open-label extension trial is to evaluate long-term safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in diabetic patients with peripheral arterial occlusive disease (PAOD) and peripheral neuropathy.
NCT00942968 ↗	Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer	Completed	Eisai Inc.	Phase 4	2009-06-01	The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.

Clinical Trial Conditions for dalteparin sodium

Condition Name

Condition Name for dalteparin sodium
Intervention	Trials
Venous Thromboembolism	7
Diabetic Foot Ulcer	1
Thromboembolism	1
Lower Extremity Superficial Thrombophlebitis	1

Condition MeSH

Condition MeSH for dalteparin sodium
Intervention	Trials
Venous Thromboembolism	8
Thromboembolism	8
Thrombosis	4
Venous Thrombosis	3

Clinical Trial Locations for dalteparin sodium

Trials by Country

Trials by Country for dalteparin sodium
Location	Trials
United States	36
Canada	23
Russian Federation	5
Spain	3
Netherlands	2

Trials by US State

Trials by US State for dalteparin sodium
Location	Trials
District of Columbia	3
Oklahoma	2
Missouri	2
Colorado	2
Virginia	2

Clinical Trial Progress for dalteparin sodium

Clinical Trial Phase

Clinical Trial Phase for dalteparin sodium
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	4
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for dalteparin sodium
Clinical Trial Phase	Trials
Completed	11
Terminated	3
Enrolling by invitation	1

Clinical Trial Sponsors for dalteparin sodium

Sponsor Name

Sponsor Name for dalteparin sodium
Sponsor	Trials
Pfizer	8
University of Oklahoma	2
Eisai Inc.	2

Sponsor Type

Sponsor Type for dalteparin sodium
Sponsor	Trials
Other	14
Industry	11
NIH	1